Isomorphic Labs in talks to raise about $5 billion at roughly $50 billion valuation
Isomorphic Labs, a spinout of Google DeepMind under Alphabet, is reportedly in talks to raise roughly $5 billion in new capital. Sources say the financing would lift the AI drug‑discovery startup’s valuation to about $50 billion, a level that would place it among the most valuable biotech ventures.
Key points
- Isomorphic Labs, a Google DeepMind spinout, is reportedly seeking about $5 billion in new funding.
- The fundraising would value the AI drug‑discovery startup at roughly $50 billion, according to sources.
- The company previously raised $2.1 billion in May, Bloomberg reported.
Bloomberg notes the company secured $2.1 billion in a previous round in May. The additional funds are expected to expand its computational chemistry platform, speed up drug‑candidate screening, and deepen collaborations with pharmaceutical partners. The move underscores the growing investor appetite for artificial‑intelligence tools that can shorten the drug‑development timeline and lower costs.
The story so far
4 episodes →- Isomorphic Labs in talks to raise about $5 billion at roughly $50 billion valuationthis story
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Business & Funding
All →- Microsoft’s Azure cloud contracts hit $677B as 10 US cities ban new data centers · 1 src
- Anthropic’s Cat Wu joins OpenAI to lead core product management · 4 src
- Nvidia backs AI projects with $300bn in guarantees, raising risks · 4 src
- Uber reports 4 rides from AI agents in Q3 2026 · 3 src
- OpenAI to acquire Pierre Computer Company, Inc. · 5 src
Comments
via GitHub Discussions